In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Crohn's Disease: European Contenders Lead

Executive Summary

Companies--in particular Europeans--are developing plenty of new biotech treatments for Crohn's disease. But the regulatory path is tough. This painful inflammatory bowel disease is complex and intermittent and responds well to placebo. As such, companies routinely miss primary endpoints-as was recently the case for Elan's Antegren and Schering's Leukine. But Antegren, Celltech's CDP-870, and Leukine could, if approved, reshape their owner's prospects-and potentially give Europe's small-and mid-sized firms the boost they need.

You may also be interested in...

Celltech Gets Second Bite of CDP 870 Cherry

When Big Pharma companies hand back licensed products to their biotech originators it's generally considered bad news for the biotech. But it needn't always be so. Pfizer's decision to return rights to Celltech's anti-inflammatory antibody CDP 870 hit Celltech's share price hard, but could ultimately open up a wealth of options and opportunities to the company.

Actelion: A Model for European Biotech

Actelion reached profitability in record time by focusing from the start on the development and commercial end of the business. It in-licensed an unusually late-stage pipeline made up of compounds its founders helped develop, and built its own global sales and marketing infrastructure to maximize the value of its projects. Now Actelion plans to leverage growing profits to go back and nurture earlier stage research-a top-down biotech-building model that may prove inspirational to others.

Elan Recovery Slowed By King

King Pharmaceuticals' decision to abandon its $850 million purchase of Elan's primary care franchise is the first serious setback to the embattled Irish firm's recovery plan. But with several remaining saleable assets and a potential blockbuster in Phase III autoimmune therapy Antegren, all is not lost.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts